Sign up
Quantellect · Analysts · Analyst Profile
Q Score Rank#243 of 388

Matthew Harrison

Morgan Stanley · Equity Research Analyst
ProvisionalRating since 2017No new ratings since Jul 2025

Analyst rating accuracy & track record

Matthew Harrison is an equity research analyst at Morgan Stanley. Quantellect has scored 36 of their stock calls across 10 companies. Their picks beat their sector 44% of the time over the next 12 months, and their price targets were reached 46% of the time within a year.

Win % vs sector
44%
PT Hit % (12mo)
46%
Avg sector-excess
−9.6%
Scored calls
36
Tickers
10
Tier
Provisional

Track record

Quantellect has scored 36 of Matthew Harrison's stock calls across 10 companies, dating back to 2017. Their rated stocks beat their own sector 44% of the time over the next 12 months. On a typical call, a Harrison pick returned −9.6% more than its sector over the following year.

Of the scored calls, 26 were bullish (Buy) and 10 were bearish (Sell). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
LEGNLegend Biotech Corp
Buy$81.00Jul 2025−51.0%Miss
TNYATenaya Therapeutics Inc
Buy$5.00Mar 2025+27.0%Miss
DNLIDenali Therapeutics Inc
Buy$33.00Mar 2025+36.2%Miss
ALECAlector Inc
Sell$3.00Nov 2024+56.7%Hit
PHVSPharvaris BV
Buy$34.00Apr 2024−26.2%Miss
PHVSPharvaris BV
Buy$34.00Apr 2024−34.5%Miss
PHVSPharvaris BV
Buy$35.00Dec 2023−36.0%Miss
PHVSPharvaris BV
Buy$32.00Nov 2023+5.6%Hit
ZNTLZentalis Pharmaceuticals Llc
Buy$38.00Nov 2023−78.9%Miss
PHVSPharvaris BV
Buy$34.00Aug 2023−30.5%Miss
INVAInnoviva Inc
Sell$10.00Mar 2023−23.4%Miss
ONCBeiGene, Ltd.
Buy$321.00Feb 2023−41.3%Miss
INVAInnoviva Inc
Sell$13.00Jan 2023−26.0%Hit
AVIRAtea Pharmaceuticals Inc
Sell$4.00Jan 2023+25.6%Hit
ADAGAdagene Inc
Buy$5.00Jan 2023+99.7%Miss
ONCBeiGene, Ltd.
Buy$325.00Jan 2023−44.6%Miss
INVAInnoviva Inc
Sell$14.00Oct 2022+6.2%Hit
ONCBeiGene, Ltd.
Buy$295.00Oct 2022+7.9%Miss
ADAGAdagene Inc
Buy$7.00Sep 2022−11.7%Miss
AVIRAtea Pharmaceuticals Inc
Sell$7.00Aug 2022+64.1%Hit
INVAInnoviva Inc
Sell$13.00Aug 2022+9.4%Hit
INVAInnoviva Inc
Sell$12.00Jul 2022+18.6%Hit
ONCBeiGene, Ltd.
Buy$293.00Jul 2022+10.0%Miss
INVAInnoviva Inc
Sell$13.00Apr 2022+37.1%Hit
ONCBeiGene, Ltd.
Buy$338.00Apr 2022+38.1%Miss
ADAGAdagene Inc
Buy$15.00Feb 2022−76.4%Miss
AVIRAtea Pharmaceuticals Inc
Sell$7.00Jan 2022+41.0%Hit
AVIRAtea Pharmaceuticals Inc
Buy$37.00Aug 2021−71.0%Hit
ONCBeiGene, Ltd.
Buy$407.00Aug 2021−32.5%Hit
ADAGAdagene Inc
Buy$33.00Jul 2021−90.9%Miss
AVIRAtea Pharmaceuticals Inc
Buy$35.00Jun 2021−71.6%Hit
ONCBeiGene, Ltd.
Buy$409.00Jun 2021−67.7%Hit
AVIRAtea Pharmaceuticals Inc
Buy$82.00Apr 2021−109.6%Miss
ONCBeiGene, Ltd.
Buy$184.00Apr 2020+72.1%Hit
ONCBeiGene, Ltd.
Buy$200.00Mar 2018−32.1%Hit
ONCBeiGene, Ltd.
Buy$95.00Oct 2017+13.2%Hit
Go to

Matthew Harrison: analyst track record FAQ

Is Matthew Harrison a good stock analyst?

Yes, by track record. Matthew Harrison ranks number 243 of 388 of the analysts Quantellect scores, with a Q Score of 21 out of 100. Past results do not guarantee future ones.

What is Matthew Harrison's win rate?

Matthew Harrison's win rate is 44%. Across 36 scored calls, their rated stocks beat their sector 44% of the time over the next 12 months. On a typical call they returned −9.6% more than the sector.

What stocks and sectors does Matthew Harrison cover?

Matthew Harrison covers 10 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Matthew Harrison's price targets accurate?

Matthew Harrison's price targets are reached within 12 months 46% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Matthew Harrison's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Matthew Harrison rank among Wall Street analysts?

Matthew Harrison ranks number 243 of 388 by Q Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.